 Phase trial indium anti-epidermal growth factor receptor monoclonal antibody patients squamous cell lung carcinoma Murine monoclonal antibody MAb epidermal growth factor EGF receptor EGF binding EGF-induced activation receptor tyrosine kinase cell proliferation effect MAb phase trial patients inoperable squamous cell carcinoma lung high levels EGF receptors Groups patients total doses MAb mg mg dose infusion mg indium MAb toxicity Tumors patients doses mg metastases equal cm diameter doses mg Single-photon-emission-computed tomography doses tumor visualization patients anti-murine antibodies treatment MAb EGF receptor function safe doses schedule MAb squamous cell lung carcinoma uptake labeled MAb dose dependent Further studies potential therapeutic efficacy anti-EGF receptor MAbs agents comparable manner